Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vyome Holdings Inc (HIND)

Vyome Holdings Inc (HIND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,090
  • Shares Outstanding, K 7,018
  • Annual Sales, $ 320 K
  • Annual Income, $ -10,260 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.34
  • Price/Sales 44.74
  • Price/Cash Flow N/A
  • Price/Book 3.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.02 +5.07%
on 03/18/26
3.45 -38.41%
on 03/02/26
-1.25 (-37.02%)
since 02/27/26
3-Month
1.75 +21.29%
on 02/02/26
3.89 -45.44%
on 01/27/26
-1.32 (-38.30%)
since 12/31/25
52-Week
1.75 +21.29%
on 02/02/26
71.51 -97.03%
on 04/04/25
-156.88 (-98.67%)
since 04/01/25

Most Recent Stories

More News
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive...

HIND : 2.12 (-1.28%)
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026

LICH : 0.0100 (unch)
HIND : 2.12 (-1.28%)
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety Plans to generate human clinical...

HIND : 2.12 (-1.28%)
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M ...

HIND : 2.12 (-1.28%)
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product

HIND : 2.12 (-1.28%)
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion Modeled peak annual U.S. sales approaching USD 600 million for VT-1953 ...

HIND : 2.12 (-1.28%)
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Board completes review of strategic alternatives for LICH, executes critical first step in building a scalable, standalone business

LICH : 0.0100 (unch)
HIND : 2.12 (-1.28%)
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002). ...

HIND : 2.12 (-1.28%)
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs

HIND : 2.12 (-1.28%)
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

(Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure ...

HIND : 2.12 (-1.28%)

Business Summary

Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.38
2nd Resistance Point 2.30
1st Resistance Point 2.23
Last Price 2.12
1st Support Level 2.08
2nd Support Level 2.00
3rd Support Level 1.93

See More

52-Week High 71.51
Fibonacci 61.8% 44.86
Fibonacci 50% 36.63
Fibonacci 38.2% 28.40
Last Price 2.12
52-Week Low 1.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.